Jeremy Bender, Day One Biopharmaceuticals CEO

Two days af­ter show­ing strong pe­di­atric can­cer da­ta, Day One taps $150M in pub­lic cap­i­tal

Pub­lic biotechs can still raise mon­ey, but it comes with a big caveat: The clin­i­cal da­ta must im­press.

It ap­pears the mar­ket re­act­ed so with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.